Best practices for bioinformatic characterization of neoantigens for clinical utility
Open accessThe DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition. Recently, researchers and clinicians have leveraged next generation sequencing technologies to identify neoantigens and to create personalized immunotherapies for cancer treatment. To create a personalized cancer vaccine, neoantigens must be computationally predicted from matched tumor-normal sequencing data, and then ranked according to their predicted capability in stimulating a T cell response. This candidate neoantigen prediction process involves multiple steps, including somatic mutation identification, HLA typing, peptide processing, and peptide-MHC binding prediction. The general workflow has been utilized for many preclinical and clinical trials, but there is no current consensus approach and few established best practices. In this article, we review recent discoveries, summarize the available computational tools, and provide analysis considerations for each step, including neoantigen prediction, prioritization, delivery, and validation methods. In addition to reviewing the current state of neoantigen analysis, we provide practical guidance, specific recommendations, and extensive discussion of critical concepts and points of confusion in the practice of neoantigen characterization for clinical use. Finally, we outline necessary areas of development, including the need to improve HLA class II typing accuracy, to expand software support for diverse neoantigen sources, and to incorporate clinical response data to improve neoantigen prediction algorithms. The ultimate goal of neoantigen characterization workflows is to create personalized vaccines that improve patient outcomes in diverse cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–207 of 207
Comprehensive benchmarking of SNV callers for highly admixed tumor data
Bohnert, R., Vivas, S., & Jansen, G. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186175 · Cited by 26 · cited 1×
“For calling indels, in addition to Strelka, EBCall [40] demonstrates the least sensitivity to coverage variability [41, 42].”
MethodPredictor for the effect of amino acid composition on CD4+ T cell epitopes preprocessing
Hoze, E., Tsaban, L., Maman, Y., & Louzoun, Y. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.02.006 · Cited by 24
AltORFev facilitates the prediction of alternative open reading frames in eukaryotic mRNAs
Kochetov, A. V., Allmer, J., Klimenko, A. I., Зураев, Б. С., Matushkin, Y. G., & Lashin, S. A. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw736 · Cited by 14 · cited 1×
“Several computational tools exist to predict post-translational modifications and alternative translation events from sequencing data, such as GPS [157] and KinasePhos [158] for phosphorylation events and altORFev [159] for alternative ORFs.”
MethodComprehensive discovery of noncoding RNAs in acute myeloid leukemia cell transcriptomes
Zhang, J., Griffith, M., Miller, C. A., Griffith, O. L., Spencer, D. H., Walker, J., Magrini, V. J., McGrath, S. D., Ly, A., Helton, N., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.07.008 · Cited by 11 · cited 1×
“A lack of evidence for expression in RNA-seq data may not be definitive evidence of non-expression of a variant because not all genes can be robustly profiled by RNA-seq (for example, very small genes may be poorly detected by standard RNA-seq libraries [205]).”
BackgroundSelf-citationGFusion: an Effective Algorithm to Identify Fusion Genes from Cancer RNA-Seq Data
Zhao, J., Chen, Q., Wu, J., Han, P., & Song, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-07070-6 · Cited by 10 · cited 1×
“Many tools have been developed to predict fusion genes from RNA-seq and/or whole genome sequencing (WGS) data; recent tools include pizzly [47], STAR-fusion [48], JAFFA [49], GFusion [50], and INTEGRATE [51] (refer to Table 1).”
neoepiscope improves neoepitope prediction with multi-variant phasingPreprint
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/418129 · Cited by 8
Intron retention as a novel source of cancer neoantigensPreprint
Smart, A., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D. O., Fugmann, T., Wong, K., & Allen, E. M. V. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/309450 · Cited by 6
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538
Self-citationNeoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
Self-citationRNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets
Pan, Y., Kadash-Edmondson, K. E., Wang, R., Phillips, J., Liu, S., Ribas, A., Aplenc, R., Witte, O. N., & Xing, Y. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.006 · Cited by 53
Metadata
- Authors
- Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M.
- Venue
- Genome Medicine
- Published
- 2019-08-28
- Volume
- 11
- Issue
- 1
- Pages
- 56-56
- ISSN
- 1756-994X (ISSN-L)
- OpenAlex
- W2971041153
- Cited by
- 214
- References
- 207
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.